Phase Holographic

Peter Egelberg:
As executive chairman, I will focus on strategic partnerships. Transforming healthcare by industrializing regenerative medicine and the manufacturing of cell-based therapies is an ambitious project. Besides academic alliances, it will require industrial and regulatory partnerships involving major software companies, life science tools companies and regulatory agencies.

Patrik Eschricht:
With my previous background in senior positions in companies during rapid growth, I feel well equipped to take on the daily leadership and drive the two objectives the Board has presented me with: further increase sales and develop PHI’s HoloMonitor technology in regenerative medicine. Together with our partners, we are setting the standards for automated quality control systems in regenerative medicine.